A retrospective study identified Grade 3-4 pneumonitis in 3% of patients treated with the combination of ipilimumab and nivolumab compared with 0.7% in the anti-PD-1/PD-L1 group [24]. The gene discussed is CD274; the disease is pneumonitis.